OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
19
Results
Show all
Save search
Copy query
Show results for
Unknown
(13)
Proteomics
(4)
Transcriptomics
(2)
Organisms
Homo sapiens
(6)
Repository
pride
(4)
biostudies-arrayexpress
(2)
Tissue
Cell culture
(1)
Melanocyte
(1)
Disease
Melanoma
(1)
Technology Type
Mass Spectrometry
(4)
Shotgun proteomics
(4)
Publication Date
2018
(4)
2014
(2)
Study type
Transcription profiling by array
(2)
Release Date
2014
(3)
2022
(2)
2016
(2)
2024
(1)
2021
(1)
2020
(1)
2019
(1)
2018
(1)
2017
(1)
2015
(1)
2013
(1)
Lab affiliation
Janne Lehtiö Science for Life Laboratory/Karolinska Institutet Cancer Proteomics Mass spectrometry Tomtebodavägen 23 171 76 Solna Sweden
(1)
KTH, School of Biotechnology
(1)
School of Biotechnology, KTH
(1)
School of Biotechnology, KTH, Sweden
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance.
Not available
S-EPMC4021518
|
biostudies-literature
Cite
Effect of glucocorticoids for the management of immune-related adverse events on outcome in melanoma patients treated with immunotherapy-a retrospective and biomarker study.
Not available
S-EPMC11215956
|
biostudies-literature
Cite
Proliferation and Immune Response Gene Signatures Associated with Clinical Outcome to Immunotherapy and Targeted Therapy in Metastatic Cutaneous Malignant Melanoma.
Not available
S-EPMC9331037
|
biostudies-literature
Cite
Metabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous ovarian cancer.
Not available
S-EPMC3874631
|
biostudies-literature
Cite
Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.
Not available
S-EPMC6737096
|
biostudies-literature
Cite
Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib.
Not available
S-EPMC7469874
|
biostudies-literature
Cite
Hsp90i resistance - Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
The goal is to describe the mechanisms underlying the resistance of melanoma against Hsp90i using (phospho)proteomics
ORGANISM(S):
Homo sapiens (Human)
2018-02-26
|
PXD005518
|
Pride
Proteomics
phosphoproteomics
lc/ms/ms
hsp90i
Cite
Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
Not available
S-EPMC5596587
|
biostudies-literature
Cite
Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors.
Not available
S-EPMC5836539
|
biostudies-literature
Cite
CETSA Hsp90i - Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
The goal of this project is to identify the drug target of XL888, an hsp90i used in clinical trial against melanoma
ORGANISM(S):
Homo sapiens (Human)
2018-02-13
|
PXD005508
|
Pride
Cetsa-ms
brp
lc/ms/ms
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
